WO2024029392A1 - Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof - Google Patents
Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof Download PDFInfo
- Publication number
- WO2024029392A1 WO2024029392A1 PCT/JP2023/027091 JP2023027091W WO2024029392A1 WO 2024029392 A1 WO2024029392 A1 WO 2024029392A1 JP 2023027091 W JP2023027091 W JP 2023027091W WO 2024029392 A1 WO2024029392 A1 WO 2024029392A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ergothioneine
- salt
- collagen
- derived
- weight
- Prior art date
Links
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 title claims abstract description 105
- 229940093497 ergothioneine Drugs 0.000 title claims abstract description 100
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 150000003839 salts Chemical class 0.000 title claims abstract description 65
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 65
- 108010035532 Collagen Proteins 0.000 claims abstract description 65
- 229920001436 collagen Polymers 0.000 claims abstract description 64
- 235000013305 food Nutrition 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- -1 inorganic acid salts Chemical class 0.000 description 6
- 241000282887 Suidae Species 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 240000002769 Morchella esculenta Species 0.000 description 3
- 235000002779 Morchella esculenta Nutrition 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- BMUXBWLKTHLRQC-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O BMUXBWLKTHLRQC-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 244000251953 Agaricus brunnescens Species 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- 235000007710 Grifola frondosa Nutrition 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 241000222350 Pleurotus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- VJVNJHQBYWPXEK-TVKLMDQASA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid Chemical compound NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VJVNJHQBYWPXEK-TVKLMDQASA-N 0.000 description 1
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000222455 Boletus Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- GLLRIXZGBQOFLM-UHFFFAOYSA-N Xanthorin Natural products C1=C(C)C=C2C(=O)C3=C(O)C(OC)=CC(O)=C3C(=O)C2=C1O GLLRIXZGBQOFLM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108090000350 actinidain Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
Definitions
- the present invention relates to an oral composition containing ergothioneine or a salt thereof and porcine-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000.
- the present invention also relates to a method for suppressing bitterness derived from ergothioneine or a salt thereof.
- Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability.
- Patent Document 1 reports an immune response-activating cytokine production promoting effect. Since ergothioneine has a variety of physiological activities, it has recently attracted attention as a food, cosmetic, and pharmaceutical product.
- ergothioneine since ergothioneine has useful physiological activity, foods such as supplements containing ergothioneine or its salt are useful for maintaining or promoting health. However, ergothioneine or its salt has a unique flavor, especially an unpleasant bitter taste that stings the tongue, and there is room for improvement in making it into an oral composition.
- the present inventors found that when ergothioneine or its salt is combined with pig-derived collagen having a weight average molecular weight of more than 1,000 and 10,000 or less, the bitterness derived from ergothioneine or its salt can be reduced. We have found that it can be effectively suppressed.
- the present invention includes the following compositions.
- An oral composition comprising (A) ergothioneine or a salt thereof, and (B) porcine-derived collagen having a weight average molecular weight of greater than 1,000 and less than or equal to 10,000.
- (A) A method for suppressing the bitter taste derived from ergothioneine or its salt in an oral composition containing ergothioneine or its salt, the oral composition having (B) a weight average molecular weight of greater than 1000 and less than or equal to 10000.
- Component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700. The method described in [4].
- an oral composition containing ergothioneine or a salt thereof with reduced bitterness derived from ergothioneine or a salt thereof it is possible to provide a method for suppressing the bitter taste derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or a salt thereof.
- composition of the present invention comprises (A) ergothioneine or a salt thereof; and (B) collagen derived from pigs having a weight average molecular weight of more than 1000 and less than 10000; Contains.
- Ergothioneine is a type of sulfur-containing amino acid.
- ergothioneine is preferably L-ergothioneine.
- the salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for foods and drinks, and may be either an acidic salt or a basic salt.
- Acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates; acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates; Examples include organic acid salts such as acid salts and propionate salts.
- Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.
- Ergothioneine or its salt is not limited in any way by its form or manufacturing method. Ergothioneine or a salt thereof may be a chemically synthesized product or may be extracted and purified from a natural product.
- L-ergothioneine is abundantly contained in Golden/Yellow Oyster mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom of the Pleurotus family and Pleurotus genus.
- L-ergothioneine is extracted from Agaricus bisporus (scientific name: Agaricus bisporus), Gray Oyster Mushroom (scientific name: Pleurotus ostreatus), such as white button mushrooms, crimini mushrooms, and Portabella mushrooms.
- shiitake (scientific name: Lentinula edodes), maitake (Scientific name: Grifola Frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybe aegerita), Chanterelle (Scientific name: Ca) ntharellus cibarius), boletus (scientific name: Boletus edulis), morel mushroom ( It is also included in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta).
- L-ergothioneine is obtained from a natural product, it is preferably extracted from Tamogitake mushrooms. Ergothioneine or its salt can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
- collagen generally refers to collagen protein.
- the production method of collagen is not particularly limited as long as it is derived from pigs.
- Collagen in the present invention also includes collagen peptides obtained by hydrolyzing porcine-derived collagen or denatured collagen such as gelatin with enzymes, acids, alkalis, etc.
- One type of collagen may be used alone, or two or more types of collagen may be used in combination.
- the enzyme used in the above hydrolysis treatment may be any enzyme as long as it can cleave the peptide bonds of collagen or gelatin, such as collagenase, papain, bromelain, actinidin, ficin, cathepsin, pepsin, chymosin, trypsin, and the like.
- examples include enzyme preparations containing a mixture of enzymes.
- As the acid for example, hydrochloric acid, sulfuric acid, nitric acid, etc. can be used.
- As the alkali for example, sodium hydroxide, calcium hydroxide, etc. can be used.
- an aqueous solution of hydrolyzed collagen may be used as it is, or a powder obtained by drying or the like may be used. Further, the aqueous solution may be subjected to a commonly used purification treatment and used in the form of an aqueous solution, powder, or the like.
- collagen having a weight average molecular weight of more than 1,000 and less than 10,000 can be used.
- examples of commercially available products include "SCP-50NB” (manufactured by Nitta Gelatin Co., Ltd.).
- the weight average molecular weight of the collagen used in the present invention is greater than 1,000 and less than 10,000, preferably from 1,500 to 9,500, and more preferably from 2,000 to 9,000. If the weight average molecular weight is less than 1,000, there is a risk that the bitter taste accompanied by the odor characteristic of low molecular weight collagen will be strong, and if it is greater than 10,000, there is a risk that solubility and absorbability will be low.
- the weight average molecular weight of collagen means a value measured by relative molecular mass measurement method for fish oligopeptide powder according to Chinese National Standard (GB Standard) GB/T 22729-2008. However, substitutes are used for the reagents M, 451 and M, 189.
- the weight average molecular weight in this method is determined by the following: cell pigment C (cytochrome, M, 6500), trasylol (aprotinin, M, 12500), bacillus (bacitracin, M, 1450), glycine-glycine- It is calculated based on a relative molecular mass calibration curve of the relationship between retention time and logarithm of relative molecular weight obtained by measuring tyrosine-arginine (M, 451) and glycine-glycine-glycine (M, 189) under the same conditions.
- the weight average molecular weight in the present invention refers to the weight average molecular weight calculated in terms of each standard product according to this method.
- the composition of the present invention has reduced bitterness derived from ergothioneine or a salt thereof by containing collagen having a weight average molecular weight of more than 1,000 and less than 10,000. Therefore, continuous intake of ergothioneine or its salt becomes easy.
- the weight ratio ((B)/(A)) of component (B) to component (A) is not particularly limited, but may be 1 to 1000. When the weight ratio of component (B) to component (A) (in terms of ergothioneine) is within the above range, the bitterness derived from component (A) can be sufficiently suppressed.
- Pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 has a unique odor reminiscent of animal odor.
- the odor derived from the collagen can also be suppressed.
- the weight ratio ((B)/(A)) of component (B) to component (A) is preferably 5 to 700.
- the above weight ratio is more preferably 7 to 400, still more preferably 10 to 300, particularly preferably 10 to 100.
- component (A) when component (A) is ergothioneine, the amount in terms of ergothioneine or a similar expression means the amount, and when component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
- the content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
- the content of ergothioneine or its salt contained in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.2% by weight or more, further preferably 0.3% by weight or more in terms of ergothioneine. It is preferably 50% by weight or less, more preferably 40% by weight or less, even more preferably 30% by weight or less, even more preferably 20% by weight or less, particularly preferably 10% by weight or less.
- the content of ergothioneine or its salt contained in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.1 to 40% by weight, and more preferably 0.2 to 40% by weight, in terms of ergothioneine. More preferably 30% by weight, even more preferably 0.2 to 20% by weight, particularly preferably 0.3 to 10% by weight.
- the content of the ergothioneine or its salts is the total content thereof.
- the content of ergothioneine can be measured by high performance liquid chromatography (HPLC).
- the content of pig-derived collagen, which has a weight average molecular weight of more than 1,000 and less than 10,000, contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
- the content of the collagen contained in the composition of the present invention is, for example, preferably 1% by weight or more, more preferably 5% by weight or more, even more preferably 10% by weight or more, even more preferably 30% by weight or more, and even more preferably 50% by weight or more. It is particularly preferably at least 99.9% by weight, more preferably at most 99.8% by weight, even more preferably at most 99.5% by weight.
- the content of the collagen contained in the composition of the present invention is preferably 1 to 99.9% by weight, more preferably 10 to 99.8% by weight, and even more preferably 50 to 99.5% by weight. .
- the collagen content is the total content of these. Collagen content can be measured by HPLC method.
- the content of ergothioneine or its salt is preferably 1 to 100 mg, more preferably 2 to 50 mg, and more preferably 5 to 25 mg in terms of ergothioneine per daily intake for adults. More preferably, the amount is 5 to 20 mg, particularly preferably 5 to 20 mg.
- the content of pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 is preferably 500 to 20,000 mg, and preferably 1,000 to 15,000 mg, per adult's daily intake. is more preferable, and even more preferably 3,000 to 10,000 mg.
- Ergothioneine or a salt thereof and porcine-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 are compounds that are included in natural products and food and drink products and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or a salt thereof and collagen derived from pigs having a weight average molecular weight of more than 1,000 and less than 10,000 are considered to pose few problems when ingested, for example, every day. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or its salt, and is easy to ingest.
- composition of the present invention can be used for antioxidant purposes, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for suppressing melanin production, for eliminating reactive oxygen species, and for inhibiting elastase activity. It can be suitably used for suppressing wrinkle formation, suppressing skin sagging, promoting autophagy, etc.
- Collagen is known to exert various health functions such as beautifying the skin by improving skin moisture retention and elasticity, and improving blood fluidity. Since the composition of the present invention contains pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000, it can also be used to obtain the above-mentioned effects exerted by collagen.
- compositions of the invention can be applied for either therapeutic (medical) or non-therapeutic (non-medical) uses.
- Non-therapeutic is a concept that does not include medical procedures, ie, surgery, treatment, or diagnosis of humans.
- composition of the present invention can be in the form of a food or drink, a drug, a quasi-drug, a feed, or the like.
- the composition of the present invention may be a material or a preparation used by being mixed into foods and drinks, pharmaceuticals, quasi-drugs, feeds, and the like.
- the composition of the present invention is an oral composition, and specific examples of the oral composition include food and drink products, oral pharmaceuticals, quasi-drugs, feeds, etc., and preferably food and drink products or oral compositions. It is a medicine, and more preferably a food or drink.
- the composition of the present invention contains, in addition to ergothioneine or a salt thereof and porcine collagen having a weight average molecular weight of more than 1,000 and less than 10,000, any additives and ingredients, as long as the effects of the present invention are not impaired. can do.
- These additives and components can be selected depending on the form of the composition, etc., and those that can be generally used in oral compositions such as foods and drinks, pharmaceuticals, quasi-drugs, and feeds can be used.
- the manufacturing method thereof is not particularly limited, and it can be manufactured by a general method.
- the composition of the present invention may consist of ergothioneine or a salt thereof and a pig-derived collagen having a weight average molecular weight of greater than 1,000 and less than or equal to 10,000.
- the form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
- composition of the present invention when used as a food or drink, ergothioneine or a salt thereof and porcine-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 are combined with ingredients that can be used in foods and drinks (e.g., food materials, as necessary).
- Various food and drink products can be prepared by blending food additives (accordingly used food additives, etc.).
- Foods and drinks are not particularly limited, and include, for example, general foods and drinks, health foods, health supplements, health drinks, foods with functional claims, foods for specified health uses, foods and drinks for patients, and the like.
- the above health foods, health supplements, foods with functional claims, foods for specified health uses, etc. include fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used in various formulations such as tablets and liquid foods.
- composition of the present invention When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, ergothioneine or a salt thereof and porcine collagen having a weight average molecular weight of more than 1,000 and less than 10,000 are combined with a pharmacologically acceptable carrier, as necessary.
- a pharmacologically acceptable carrier By blending additives and the like that are added according to the conditions, various dosage forms of pharmaceuticals or quasi-drugs can be made.
- Such carriers, additives, etc. may be pharmacologically acceptable ones that can be used in pharmaceuticals or quasi-drugs, such as excipients, binders, disintegrants, lubricants, One or more of antioxidants, colorants, etc. may be used.
- Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables, and the like.
- composition of the present invention When the composition of the present invention is used as feed, ergothioneine or a salt thereof and collagen derived from pigs having a weight average molecular weight of more than 1,000 and less than 10,000 may be added to the feed.
- Feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.
- composition of the present invention is ingested or administered (also referred to as the subject of administration) is not particularly limited.
- it is a human or non-human mammal, more preferably a human.
- the present invention also includes the following method.
- ergothioneine or a salt thereof a pig-derived collagen having a weight average molecular weight of more than 1000 and less than 10000, and preferred embodiments thereof are the same as in the composition of the present invention described above.
- the blending ratio of component (B) to component (A) is not particularly limited, but the preferred range is the component (A) in the composition of the present invention (in terms of ergothioneine). It is the same as the weight ratio of (B).
- component (B) when component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700, component ( Both the bitterness originating from A) and the odor originating from component (B) can be suppressed, which is preferable.
- bitter taste suppression methods include, for example, adding a sweetener or flavoring agent to a bitter component to formulate a formulation, coating the bitter component with sugar coating, or encapsulating it in a capsule. Examples include methods of converting
- the numerical range expressed by a lower limit value and an upper limit value includes the lower limit value and upper limit value.
- the range represented by "1 to 2" means 1 or more and 2 or less, and includes 1 and 2.
- the upper limit and the lower limit may be any combination of ranges.
- the weight average molecular weight of collagen was measured using the Chinese National Standard (GB Standard) GB/T 22729-2008 relative molecular mass measurement method for fish oligopeptide powder.
- GB Standard Chinese National Standard
- M,451 and M,189 glycine-glycine-tyrosine-arginine
- M,189 glycine-glycine-glycine-glycine
- Example 1 Flavor evaluation test for oral composition containing ergothioneine and collagen> An oral composition containing ergothioneine and collagen was prepared, and three panelists skilled in sensory evaluation performed sensory evaluation. Compositions of Samples 1 to 6 (oral compositions containing ergothioneine and collagen) were prepared by mixing the amounts of (A) and (B) shown in Table 1. Table 1 shows the weight ratio of (B) collagen to (A) ergothioneine ((B)/(A)) in each composition.
- Each panelist placed the entire amount of the prepared oral composition (for example, in sample 1, 10 mg of ergothioneine and 10 mg of collagen, a total of 20 mg) on their tongue, and evaluated the intensity of the bitter taste derived from ergothioneine and the intensity of the odor derived from collagen as follows. It was evaluated according to the criteria of
- Evaluation criteria for bitterness derived from ergothioneine Evaluation was made on a scale of 1 to 5 (5 levels) based on the following criteria. As a reference point, the intensity of the bitter taste derived from ergothioneine felt when raw material (A) (10 mg) was placed on the tongue was given a score of 5 (Control 1). The evaluations of the three panelists were totaled, and the average value (score) is shown in Table 1.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention addresses the problem of providing an oral composition, which contains ergothioneine or a salt thereof and in which the bitterness derived from ergothioneine or the salt thereof is suppressed, and a method for suppressing the bitterness derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or the salt thereof. The present invention relates to an oral composition containing the following components (A) and (B): (A) ergothioneine or a salt thereof; and (B) swine-derived collagen having a weight-average molecular weight of more than 1000 and not more than 10000.
Description
本発明は、エルゴチオネイン又はその塩と重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンとを含有する経口組成物に関する。また、本発明は、エルゴチオネイン又はその塩に由来する苦味を抑制する方法に関する。
The present invention relates to an oral composition containing ergothioneine or a salt thereof and porcine-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000. The present invention also relates to a method for suppressing bitterness derived from ergothioneine or a salt thereof.
エルゴチオネインは、親水性含硫アミノ酸の一つであり、抗酸化能をはじめとする多様な生理活性を有することが知られている。エルゴチオネインの生理活性に関して、例えば、特許文献１には免疫応答活性化サイトカイン産生促進作用などが報告されている。
エルゴチオネインは、多様な生理活性を有することから、近年、食品用、化粧品用や医薬用として注目されている。 Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports an immune response-activating cytokine production promoting effect.
Since ergothioneine has a variety of physiological activities, it has recently attracted attention as a food, cosmetic, and pharmaceutical product.
エルゴチオネインは、多様な生理活性を有することから、近年、食品用、化粧品用や医薬用として注目されている。 Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability. Regarding the physiological activity of ergothioneine, for example, Patent Document 1 reports an immune response-activating cytokine production promoting effect.
Since ergothioneine has a variety of physiological activities, it has recently attracted attention as a food, cosmetic, and pharmaceutical product.
上述のとおり、エルゴチオネインは有用な生理活性を有しているため、エルゴチオネイン又はその塩を含むサプリメント等の食品は、健康維持又は増進に有用である。しかしながら、エルゴチオネイン又はその塩には独特の香味、特に舌を刺すような不快な苦味（苦み）があり、経口組成物とするうえで改善する余地があった。
As mentioned above, since ergothioneine has useful physiological activity, foods such as supplements containing ergothioneine or its salt are useful for maintaining or promoting health. However, ergothioneine or its salt has a unique flavor, especially an unpleasant bitter taste that stings the tongue, and there is room for improvement in making it into an oral composition.
本発明は、エルゴチオネイン又はその塩由来の苦味が低減されたエルゴチオネイン又はその塩を含有する経口組成物を提供することを目的とする。また、本発明は、エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法を提供することを目的とする。
An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof with reduced bitterness derived from ergothioneine or a salt thereof. Another object of the present invention is to provide a method for suppressing the bitter taste derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or a salt thereof.
本発明者らは上記課題を解決すべく鋭意研究した結果、エルゴチオネイン又はその塩と、重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンとを組み合わせると、エルゴチオネイン又はその塩由来の苦味を効果的に抑制することができることを見出した。
As a result of intensive research to solve the above problems, the present inventors found that when ergothioneine or its salt is combined with pig-derived collagen having a weight average molecular weight of more than 1,000 and 10,000 or less, the bitterness derived from ergothioneine or its salt can be reduced. We have found that it can be effectively suppressed.
本発明は、以下の組成物等を包含する。
〔１〕下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲン、を含有する経口組成物。
〔２〕成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００である、上記〔１〕に記載の経口組成物。
〔３〕飲食品である、上記〔１〕又は〔２〕に記載の経口組成物。
〔４〕（Ａ）エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法であって、上記経口組成物に（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを配合する工程を含む、エルゴチオネイン又はその塩に由来する苦味を抑制する方法。
〔５〕経口組成物中の成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００となるように成分（Ｂ）を配合する、上記〔４〕に記載の方法。 The present invention includes the following compositions.
[1] The following components (A) and (B):
An oral composition comprising (A) ergothioneine or a salt thereof, and (B) porcine-derived collagen having a weight average molecular weight of greater than 1,000 and less than or equal to 10,000.
[2] The oral composition according to [1] above, wherein the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is 5 to 700.
[3] The oral composition according to [1] or [2] above, which is a food or drink.
[4] (A) A method for suppressing the bitter taste derived from ergothioneine or its salt in an oral composition containing ergothioneine or its salt, the oral composition having (B) a weight average molecular weight of greater than 1000 and less than or equal to 10000. A method for suppressing bitterness derived from ergothioneine or a salt thereof, the method comprising the step of blending collagen derived from a pig.
[5] Component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700. The method described in [4].
〔１〕下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲン、を含有する経口組成物。
〔２〕成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００である、上記〔１〕に記載の経口組成物。
〔３〕飲食品である、上記〔１〕又は〔２〕に記載の経口組成物。
〔４〕（Ａ）エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法であって、上記経口組成物に（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを配合する工程を含む、エルゴチオネイン又はその塩に由来する苦味を抑制する方法。
〔５〕経口組成物中の成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００となるように成分（Ｂ）を配合する、上記〔４〕に記載の方法。 The present invention includes the following compositions.
[1] The following components (A) and (B):
An oral composition comprising (A) ergothioneine or a salt thereof, and (B) porcine-derived collagen having a weight average molecular weight of greater than 1,000 and less than or equal to 10,000.
[2] The oral composition according to [1] above, wherein the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is 5 to 700.
[3] The oral composition according to [1] or [2] above, which is a food or drink.
[4] (A) A method for suppressing the bitter taste derived from ergothioneine or its salt in an oral composition containing ergothioneine or its salt, the oral composition having (B) a weight average molecular weight of greater than 1000 and less than or equal to 10000. A method for suppressing bitterness derived from ergothioneine or a salt thereof, the method comprising the step of blending collagen derived from a pig.
[5] Component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700. The method described in [4].
本発明によれば、エルゴチオネイン又はその塩由来の苦味が低減されたエルゴチオネイン又はその塩を含有する経口組成物を提供することができる。また、本発明によれば、エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法を提供することができる。
According to the present invention, it is possible to provide an oral composition containing ergothioneine or a salt thereof with reduced bitterness derived from ergothioneine or a salt thereof. Further, according to the present invention, it is possible to provide a method for suppressing the bitter taste derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or a salt thereof.
本発明の経口組成物（以下、「本発明の組成物」ともいう）は、（Ａ）エルゴチオネイン又はその塩、及び、（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲン、を含有する。
The oral composition of the present invention (hereinafter also referred to as "composition of the present invention") comprises (A) ergothioneine or a salt thereof; and (B) collagen derived from pigs having a weight average molecular weight of more than 1000 and less than 10000; Contains.
エルゴチオネインは、含硫アミノ酸の一種である。本発明において、エルゴチオネインは、好ましくはＬ－エルゴチオネインである。
エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。 Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine.
The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for foods and drinks, and may be either an acidic salt or a basic salt. Acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates; acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates; Examples include organic acid salts such as acid salts and propionate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.
エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。 Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine.
The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for foods and drinks, and may be either an acidic salt or a basic salt. Acid salts include, for example, inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates; acetates, citrates, maleates, malates, oxalates, lactates, succinates, fumarates; Examples include organic acid salts such as acid salts and propionate salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts.
エルゴチオネイン又はその塩は、その形態や製造方法等によって、何ら制限されるものではない。エルゴチオネイン又はその塩は、化学合成品でもよく、天然物から抽出及び精製されたものでもよい。Ｌ－エルゴチオネインは、ヒラタケ科ヒラタケ属のキノコであるタモギタケ（Ｇｏｌｄｅｎ／Ｙｅｌｌｏｗ Ｏｙｓｔｅｒ ｍｕｓｈｒｏｏｍ）（学名：Ｐｌｅｕｒｏｔｕｓ ｃｏｒｎｕｃｏｐｉａｅ ｖａｒ． ｃｉｔｒｉｎｏｐｉｌｅａｔｕｓ）に多く含有される。Ｌ－エルゴチオネインは、ホワイトボタンマッシュルーム、クリミニマッシュルーム、ポータベラ（Ｐｏｒｔａｂｅｌｌａ）マッシュルーム等のツクリタケ（学名：Ａｇａｒｉｃｕｓ ｂｉｓｐｏｒｕｓ）、ヒラタケ（Ｇｒｅｙ Ｏｙｓｔｅｒ Ｍｕｓｈｒｏｏｍ）（学名：Ｐｌｅｕｒｏｔｕｓ ｏｓｔｒｅａｔｕｓ）、シイタケ（学名：Ｌｅｎｔｉｎｕｌａ ｅｄｏｄｅｓ）、マイタケ（学名：Ｇｒｉｆｏｌａ Ｆｒｏｎｄｏｓａ）、レイシ（学名：Ｇａｎｏｄｅｒｍａ ｌｕｃｉｄｕｍ）、ヤマブシタケ（学名：Ｈｅｒｉｃｉｕｍ ｅｒｉｎａｃｅｕｓ）、ヤナギマツタケ（学名：Ａｇｒｏｃｙｂｅ ａｅｇｅｒｉｔａ）、アンズタケ（学名：Ｃａｎｔｈａｒｅｌｌｕｓ ｃｉｂａｒｉｕｓ）、ポルチーニ（学名：Ｂｏｌｅｔｕｓ ｅｄｕｌｉｓ）、アミガサダケ（学名：Ｍｏｒｃｈｅｌｌａ ｅｓｃｕｌｅｎｔａ）等のキノコにも含まれる。天然物からＬ－エルゴチオネインを得る場合は、タモギタケから抽出等することが好ましい。エルゴチオネイン又はその塩は、微生物発酵で製造することもできる。エルゴチオネイン又はその塩は、単離されたものであってもよい。
Ergothioneine or its salt is not limited in any way by its form or manufacturing method. Ergothioneine or a salt thereof may be a chemically synthesized product or may be extracted and purified from a natural product. L-ergothioneine is abundantly contained in Golden/Yellow Oyster mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom of the Pleurotus family and Pleurotus genus. L-ergothioneine is extracted from Agaricus bisporus (scientific name: Agaricus bisporus), Gray Oyster Mushroom (scientific name: Pleurotus ostreatus), such as white button mushrooms, crimini mushrooms, and Portabella mushrooms. , shiitake (scientific name: Lentinula edodes), maitake (Scientific name: Grifola Frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybe aegerita), Chanterelle (Scientific name: Ca) ntharellus cibarius), boletus (scientific name: Boletus edulis), morel mushroom ( It is also included in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta). When L-ergothioneine is obtained from a natural product, it is preferably extracted from Tamogitake mushrooms. Ergothioneine or its salt can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
本発明において「コラーゲン」とは、一般的にコラーゲンタンパク質をいう。
コラーゲンは、ブタ由来であれば製法は特に限定されるものではない。本発明における「コラーゲン」には、ブタ由来のコラーゲン、又は、ゼラチン等の変性コラーゲンを、酵素、酸、アルカリ等で加水分解処理すること等で得られたコラーゲンペプチドも含まれる。コラーゲンは１種のコラーゲンを単独で用いてもよく、２種以上のコラーゲンを組み合わせて用いてもよい。 In the present invention, "collagen" generally refers to collagen protein.
The production method of collagen is not particularly limited as long as it is derived from pigs. "Collagen" in the present invention also includes collagen peptides obtained by hydrolyzing porcine-derived collagen or denatured collagen such as gelatin with enzymes, acids, alkalis, etc. One type of collagen may be used alone, or two or more types of collagen may be used in combination.
コラーゲンは、ブタ由来であれば製法は特に限定されるものではない。本発明における「コラーゲン」には、ブタ由来のコラーゲン、又は、ゼラチン等の変性コラーゲンを、酵素、酸、アルカリ等で加水分解処理すること等で得られたコラーゲンペプチドも含まれる。コラーゲンは１種のコラーゲンを単独で用いてもよく、２種以上のコラーゲンを組み合わせて用いてもよい。 In the present invention, "collagen" generally refers to collagen protein.
The production method of collagen is not particularly limited as long as it is derived from pigs. "Collagen" in the present invention also includes collagen peptides obtained by hydrolyzing porcine-derived collagen or denatured collagen such as gelatin with enzymes, acids, alkalis, etc. One type of collagen may be used alone, or two or more types of collagen may be used in combination.
上記加水分解処理に用いる酵素としては、コラーゲン又はゼラチンのペプチド結合を切断することができるものであればよく、例えば、コラゲナーゼ、パパイン、ブロメライン、アクチニジン、フィシン、カテプシン、ペプシン、キモシン、トリプシン、及びこれらの酵素を混合した酵素製剤等が挙げられる。酸としては、例えば、塩酸、硫酸、硝酸などを用いることができる。アルカリとしては、例えば、水酸化ナトリウム、水酸化カルシウム等を用いることができる。
The enzyme used in the above hydrolysis treatment may be any enzyme as long as it can cleave the peptide bonds of collagen or gelatin, such as collagenase, papain, bromelain, actinidin, ficin, cathepsin, pepsin, chymosin, trypsin, and the like. Examples include enzyme preparations containing a mixture of enzymes. As the acid, for example, hydrochloric acid, sulfuric acid, nitric acid, etc. can be used. As the alkali, for example, sodium hydroxide, calcium hydroxide, etc. can be used.
本発明においては、加水分解されたコラーゲンの水溶液をそのまま使用してもよいし、乾燥等により粉末化したものを用いてもよい。また、当該水溶液に通常用いられる精製処理を施したものを、水溶液や粉末等の形態として用いてもよい。
In the present invention, an aqueous solution of hydrolyzed collagen may be used as it is, or a powder obtained by drying or the like may be used. Further, the aqueous solution may be subjected to a commonly used purification treatment and used in the form of an aqueous solution, powder, or the like.
コラーゲンは市販品を用いてもよく、重量平均分子量が１０００より大きく１００００以下であるコラーゲンを使用することができる。市販品として、例えば、「ＳＣＰ－５０ＮＢ」（新田ゼラチン（株）製）等が挙げられる。
Commercially available collagen may be used, and collagen having a weight average molecular weight of more than 1,000 and less than 10,000 can be used. Examples of commercially available products include "SCP-50NB" (manufactured by Nitta Gelatin Co., Ltd.).
本発明で用いられるコラーゲンの重量平均分子量は１０００より大きく１００００以下であり、好ましくは１５００～９５００であり、より好ましくは２０００～９０００である。重量平均分子量が１０００以下であると、低分子量コラーゲン特有の臭いを伴う苦みが強くなるおそれがあり、１００００より大きいと溶解性や吸収性が低くなるおそれがある。
The weight average molecular weight of the collagen used in the present invention is greater than 1,000 and less than 10,000, preferably from 1,500 to 9,500, and more preferably from 2,000 to 9,000. If the weight average molecular weight is less than 1,000, there is a risk that the bitter taste accompanied by the odor characteristic of low molecular weight collagen will be strong, and if it is greater than 10,000, there is a risk that solubility and absorbability will be low.
本明細書において、コラーゲンの重量平均分子量は、中国国家標準規格（ＧＢ規格）ＧＢ／Ｔ ２２７２９－２００８ フィッシュオリゴペプチドパウダーに関する相対分子質量測定法にて測定した値を意味する。ただし、Ｍ，４５１及びＭ，１８９の試薬については、代替品を用いる。
本法での重量平均分子量は、あらかじめ分子量が既知である細胞色素Ｃ（ｃｙｔｏｃｈｒｏｍｅ，Ｍ，６５００）、トラジロール（ａｐｒｏｔｉｎｉｎ，Ｍ，１２５００）、バシラス菌（ｂａｃｉｔｒａｃｉｎ，Ｍ，１４５０）、グリシン－グリシン－チロシン－アルギニン（Ｍ，４５１）、グリシン－グリシン－グリシン（Ｍ，１８９）を同条件で測定して得られたリテンションタイムと相対分子量の対数の関係の相対分子質量較正曲線を元に算出する。本発明における重量平均分子量とは、この手法に従って各標準品換算で算出した重量平均分子量を言う。 As used herein, the weight average molecular weight of collagen means a value measured by relative molecular mass measurement method for fish oligopeptide powder according to Chinese National Standard (GB Standard) GB/T 22729-2008. However, substitutes are used for the reagents M, 451 and M, 189.
The weight average molecular weight in this method is determined by the following: cell pigment C (cytochrome, M, 6500), trasylol (aprotinin, M, 12500), bacillus (bacitracin, M, 1450), glycine-glycine- It is calculated based on a relative molecular mass calibration curve of the relationship between retention time and logarithm of relative molecular weight obtained by measuring tyrosine-arginine (M, 451) and glycine-glycine-glycine (M, 189) under the same conditions. The weight average molecular weight in the present invention refers to the weight average molecular weight calculated in terms of each standard product according to this method.
本法での重量平均分子量は、あらかじめ分子量が既知である細胞色素Ｃ（ｃｙｔｏｃｈｒｏｍｅ，Ｍ，６５００）、トラジロール（ａｐｒｏｔｉｎｉｎ，Ｍ，１２５００）、バシラス菌（ｂａｃｉｔｒａｃｉｎ，Ｍ，１４５０）、グリシン－グリシン－チロシン－アルギニン（Ｍ，４５１）、グリシン－グリシン－グリシン（Ｍ，１８９）を同条件で測定して得られたリテンションタイムと相対分子量の対数の関係の相対分子質量較正曲線を元に算出する。本発明における重量平均分子量とは、この手法に従って各標準品換算で算出した重量平均分子量を言う。 As used herein, the weight average molecular weight of collagen means a value measured by relative molecular mass measurement method for fish oligopeptide powder according to Chinese National Standard (GB Standard) GB/T 22729-2008. However, substitutes are used for the reagents M, 451 and M, 189.
The weight average molecular weight in this method is determined by the following: cell pigment C (cytochrome, M, 6500), trasylol (aprotinin, M, 12500), bacillus (bacitracin, M, 1450), glycine-glycine- It is calculated based on a relative molecular mass calibration curve of the relationship between retention time and logarithm of relative molecular weight obtained by measuring tyrosine-arginine (M, 451) and glycine-glycine-glycine (M, 189) under the same conditions. The weight average molecular weight in the present invention refers to the weight average molecular weight calculated in terms of each standard product according to this method.
本発明の組成物は、重量平均分子量が１０００より大きく１００００以下であるコラーゲンを含むことによって、エルゴチオネイン又はその塩に由来する苦味が低減されている。このため、エルゴチオネイン又はその塩の継続的な摂取が容易となる。
本発明の組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））は、特に限定されないが、１～１０００であってもよい。成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比が上記範囲であると、成分（Ａ）に由来する苦味を充分に抑制することができる。 The composition of the present invention has reduced bitterness derived from ergothioneine or a salt thereof by containing collagen having a weight average molecular weight of more than 1,000 and less than 10,000. Therefore, continuous intake of ergothioneine or its salt becomes easy.
In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is not particularly limited, but may be 1 to 1000. When the weight ratio of component (B) to component (A) (in terms of ergothioneine) is within the above range, the bitterness derived from component (A) can be sufficiently suppressed.
本発明の組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））は、特に限定されないが、１～１０００であってもよい。成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比が上記範囲であると、成分（Ａ）に由来する苦味を充分に抑制することができる。 The composition of the present invention has reduced bitterness derived from ergothioneine or a salt thereof by containing collagen having a weight average molecular weight of more than 1,000 and less than 10,000. Therefore, continuous intake of ergothioneine or its salt becomes easy.
In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is not particularly limited, but may be 1 to 1000. When the weight ratio of component (B) to component (A) (in terms of ergothioneine) is within the above range, the bitterness derived from component (A) can be sufficiently suppressed.
重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンには獣臭を思わせる特有の臭みがある。該コラーゲンとエルゴチオネイン又はその塩とを組み合わせることにより、該コラーゲン由来の臭みを抑制することもできる。
本発明の組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））は、好ましくは５～７００である。これにより成分（Ｂ）に由来する臭みも充分に抑制することができ、組成物がより摂取しやすいものとなる。上記重量比は、より好ましくは７～４００であり、さらに好ましくは１０～３００であり、特に好ましくは１０～１００である。
本明細書中、エルゴチオネイン換算の量又はこれに類する表現は、成分（Ａ）がエルゴチオネインの場合はその量を意味し、成分（Ａ）がエルゴチオネインの塩の場合は、当該塩のモル数に、エルゴチオネインの分子量を乗じて得られる値を意味する。 Pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 has a unique odor reminiscent of animal odor. By combining the collagen and ergothioneine or its salt, the odor derived from the collagen can also be suppressed.
In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is preferably 5 to 700. Thereby, the odor originating from component (B) can also be sufficiently suppressed, making the composition easier to ingest. The above weight ratio is more preferably 7 to 400, still more preferably 10 to 300, particularly preferably 10 to 100.
In the present specification, when component (A) is ergothioneine, the amount in terms of ergothioneine or a similar expression means the amount, and when component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
本発明の組成物において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））は、好ましくは５～７００である。これにより成分（Ｂ）に由来する臭みも充分に抑制することができ、組成物がより摂取しやすいものとなる。上記重量比は、より好ましくは７～４００であり、さらに好ましくは１０～３００であり、特に好ましくは１０～１００である。
本明細書中、エルゴチオネイン換算の量又はこれに類する表現は、成分（Ａ）がエルゴチオネインの場合はその量を意味し、成分（Ａ）がエルゴチオネインの塩の場合は、当該塩のモル数に、エルゴチオネインの分子量を乗じて得られる値を意味する。 Pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 has a unique odor reminiscent of animal odor. By combining the collagen and ergothioneine or its salt, the odor derived from the collagen can also be suppressed.
In the composition of the present invention, the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is preferably 5 to 700. Thereby, the odor originating from component (B) can also be sufficiently suppressed, making the composition easier to ingest. The above weight ratio is more preferably 7 to 400, still more preferably 10 to 300, particularly preferably 10 to 100.
In the present specification, when component (A) is ergothioneine, the amount in terms of ergothioneine or a similar expression means the amount, and when component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は特に限定されず、その形態等に応じて設定することができる。
本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、例えば、０．１重量％以上が好ましく、０．２重量％以上がより好ましく、０．３重量％以上がさらに好ましく、また、５０重量％以下が好ましく、４０重量％以下がより好ましく、３０重量％以下がさらに好ましく、２０重量％以下がさらにより好ましく、１０重量％以下が特に好ましい。
一態様において、本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、０．１～５０重量％が好ましく、０．１～４０重量％がより好ましく、０．２～３０重量％がさらに好ましく、０．２～２０重量％がさらにより好ましく、０．３～１０重量％が特に好ましい。本発明の組成物がエルゴチオネイン又はその塩を２種以上含有する場合は、上記エルゴチオネイン又はその塩の含有量は、それらの合計含有量である。エルゴチオネインの含有量は、高速液体クロマトグラフィー（ＨＰＬＣ）法により測定することができる。 The content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
The content of ergothioneine or its salt contained in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.2% by weight or more, further preferably 0.3% by weight or more in terms of ergothioneine. It is preferably 50% by weight or less, more preferably 40% by weight or less, even more preferably 30% by weight or less, even more preferably 20% by weight or less, particularly preferably 10% by weight or less.
In one embodiment, the content of ergothioneine or its salt contained in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.1 to 40% by weight, and more preferably 0.2 to 40% by weight, in terms of ergothioneine. More preferably 30% by weight, even more preferably 0.2 to 20% by weight, particularly preferably 0.3 to 10% by weight. When the composition of the present invention contains two or more types of ergothioneine or its salts, the content of the ergothioneine or its salts is the total content thereof. The content of ergothioneine can be measured by high performance liquid chromatography (HPLC).
本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、例えば、０．１重量％以上が好ましく、０．２重量％以上がより好ましく、０．３重量％以上がさらに好ましく、また、５０重量％以下が好ましく、４０重量％以下がより好ましく、３０重量％以下がさらに好ましく、２０重量％以下がさらにより好ましく、１０重量％以下が特に好ましい。
一態様において、本発明の組成物に含まれるエルゴチオネイン又はその塩の含有量は、エルゴチオネイン換算で、０．１～５０重量％が好ましく、０．１～４０重量％がより好ましく、０．２～３０重量％がさらに好ましく、０．２～２０重量％がさらにより好ましく、０．３～１０重量％が特に好ましい。本発明の組成物がエルゴチオネイン又はその塩を２種以上含有する場合は、上記エルゴチオネイン又はその塩の含有量は、それらの合計含有量である。エルゴチオネインの含有量は、高速液体クロマトグラフィー（ＨＰＬＣ）法により測定することができる。 The content of ergothioneine or its salt contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
The content of ergothioneine or its salt contained in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.2% by weight or more, further preferably 0.3% by weight or more in terms of ergothioneine. It is preferably 50% by weight or less, more preferably 40% by weight or less, even more preferably 30% by weight or less, even more preferably 20% by weight or less, particularly preferably 10% by weight or less.
In one embodiment, the content of ergothioneine or its salt contained in the composition of the present invention is preferably 0.1 to 50% by weight, more preferably 0.1 to 40% by weight, and more preferably 0.2 to 40% by weight, in terms of ergothioneine. More preferably 30% by weight, even more preferably 0.2 to 20% by weight, particularly preferably 0.3 to 10% by weight. When the composition of the present invention contains two or more types of ergothioneine or its salts, the content of the ergothioneine or its salts is the total content thereof. The content of ergothioneine can be measured by high performance liquid chromatography (HPLC).
本発明の組成物に含まれる重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンの含有量は特に限定されず、その形態等に応じて設定することができる。
本発明の組成物に含まれる上記コラーゲンの含有量は、例えば、１重量％以上が好ましく、５重量％以上がより好ましく、１０重量％以上がさらに好ましく、３０重量％以上がさらにより好ましく、５０重量％以上が特に好ましく、また、９９．９重量％以下が好ましく、９９．８重量％以下がより好ましく、９９．５重量％以下がさらに好ましい。一態様において、本発明の組成物に含まれる上記コラーゲンの含有量は、１～９９．９重量％が好ましく、１０～９９．８重量％がより好ましく、５０～９９．５重量％がさらに好ましい。上記コラーゲンの含有量は、コラーゲンを２種以上含有する場合は、これらの合計含有量である。コラーゲンの含有量は、ＨＰＬＣ法により測定することができる。 The content of pig-derived collagen, which has a weight average molecular weight of more than 1,000 and less than 10,000, contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
The content of the collagen contained in the composition of the present invention is, for example, preferably 1% by weight or more, more preferably 5% by weight or more, even more preferably 10% by weight or more, even more preferably 30% by weight or more, and even more preferably 50% by weight or more. It is particularly preferably at least 99.9% by weight, more preferably at most 99.8% by weight, even more preferably at most 99.5% by weight. In one embodiment, the content of the collagen contained in the composition of the present invention is preferably 1 to 99.9% by weight, more preferably 10 to 99.8% by weight, and even more preferably 50 to 99.5% by weight. . When two or more types of collagen are contained, the collagen content is the total content of these. Collagen content can be measured by HPLC method.
本発明の組成物に含まれる上記コラーゲンの含有量は、例えば、１重量％以上が好ましく、５重量％以上がより好ましく、１０重量％以上がさらに好ましく、３０重量％以上がさらにより好ましく、５０重量％以上が特に好ましく、また、９９．９重量％以下が好ましく、９９．８重量％以下がより好ましく、９９．５重量％以下がさらに好ましい。一態様において、本発明の組成物に含まれる上記コラーゲンの含有量は、１～９９．９重量％が好ましく、１０～９９．８重量％がより好ましく、５０～９９．５重量％がさらに好ましい。上記コラーゲンの含有量は、コラーゲンを２種以上含有する場合は、これらの合計含有量である。コラーゲンの含有量は、ＨＰＬＣ法により測定することができる。 The content of pig-derived collagen, which has a weight average molecular weight of more than 1,000 and less than 10,000, contained in the composition of the present invention is not particularly limited, and can be set depending on its form and the like.
The content of the collagen contained in the composition of the present invention is, for example, preferably 1% by weight or more, more preferably 5% by weight or more, even more preferably 10% by weight or more, even more preferably 30% by weight or more, and even more preferably 50% by weight or more. It is particularly preferably at least 99.9% by weight, more preferably at most 99.8% by weight, even more preferably at most 99.5% by weight. In one embodiment, the content of the collagen contained in the composition of the present invention is preferably 1 to 99.9% by weight, more preferably 10 to 99.8% by weight, and even more preferably 50 to 99.5% by weight. . When two or more types of collagen are contained, the collagen content is the total content of these. Collagen content can be measured by HPLC method.
本発明の組成物は、エルゴチオネイン又はその塩の含有量が、成人の１日摂取量当たり、エルゴチオネイン換算で１～１００ｍｇであることが好ましく、２～５０ｍｇであることがより好ましく、５～２５ｍｇであることがさらに好ましく、５～２０ｍｇであることが特に好ましい。
本発明の組成物は、重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンの含有量が、成人の１日摂取量当たり、５００～２００００ｍｇであることが好ましく、１０００～１５０００ｍｇであることがより好ましく、３０００～１００００ｍｇであることがさらに好ましい。 In the composition of the present invention, the content of ergothioneine or its salt is preferably 1 to 100 mg, more preferably 2 to 50 mg, and more preferably 5 to 25 mg in terms of ergothioneine per daily intake for adults. More preferably, the amount is 5 to 20 mg, particularly preferably 5 to 20 mg.
In the composition of the present invention, the content of pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 is preferably 500 to 20,000 mg, and preferably 1,000 to 15,000 mg, per adult's daily intake. is more preferable, and even more preferably 3,000 to 10,000 mg.
本発明の組成物は、重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンの含有量が、成人の１日摂取量当たり、５００～２００００ｍｇであることが好ましく、１０００～１５０００ｍｇであることがより好ましく、３０００～１００００ｍｇであることがさらに好ましい。 In the composition of the present invention, the content of ergothioneine or its salt is preferably 1 to 100 mg, more preferably 2 to 50 mg, and more preferably 5 to 25 mg in terms of ergothioneine per daily intake for adults. More preferably, the amount is 5 to 20 mg, particularly preferably 5 to 20 mg.
In the composition of the present invention, the content of pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 is preferably 500 to 20,000 mg, and preferably 1,000 to 15,000 mg, per adult's daily intake. is more preferable, and even more preferably 3,000 to 10,000 mg.
エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンは、天然物や飲食品に含まれ、食経験がある化合物である。このため安全性の観点から、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンは、例えば毎日摂取することにも問題が少ないと考えられる。本発明によれば、安全性が高く、エルゴチオネイン又はその塩に由来する苦味が低減されて摂取しやすい組成物を提供することができる。
Ergothioneine or a salt thereof and porcine-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 are compounds that are included in natural products and food and drink products and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or a salt thereof and collagen derived from pigs having a weight average molecular weight of more than 1,000 and less than 10,000 are considered to pose few problems when ingested, for example, every day. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or its salt, and is easy to ingest.
エルゴチオネイン又はその塩は、上述のとおり、多様な生理活性や健康機能を発揮することが知られており、例えば、抗酸化作用、脳機能改善効果、抗老化作用、眼疾患改善効果、美白効果、紫外線吸収効果、メラニン産生抑制効果、活性酸素種の消去作用、エラスターゼ活性阻害効果、シワ形成抑制効果、肌のたるみ抑制効果、オートファジー促進効果等が知られている。
このため、本発明の組成物は、抗酸化用、脳機能改善用、抗老化用、眼疾患用、美白用、紫外線吸収用、メラニン産生抑制用、活性酸素種の消去用、エラスターゼ活性阻害用、シワ形成抑制用、肌のたるみ抑制用、オートファジー促進用等に好適に用いることができる。 As mentioned above, ergothioneine or its salts are known to exhibit various physiological activities and health functions, such as antioxidant effects, brain function improvement effects, anti-aging effects, eye disease improvement effects, whitening effects, It is known for its ultraviolet absorbing effect, melanin production suppressing effect, active oxygen species scavenging effect, elastase activity inhibiting effect, wrinkle formation suppressing effect, skin sagging suppressing effect, autophagy promoting effect, etc.
Therefore, the composition of the present invention can be used for antioxidant purposes, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for suppressing melanin production, for eliminating reactive oxygen species, and for inhibiting elastase activity. It can be suitably used for suppressing wrinkle formation, suppressing skin sagging, promoting autophagy, etc.
このため、本発明の組成物は、抗酸化用、脳機能改善用、抗老化用、眼疾患用、美白用、紫外線吸収用、メラニン産生抑制用、活性酸素種の消去用、エラスターゼ活性阻害用、シワ形成抑制用、肌のたるみ抑制用、オートファジー促進用等に好適に用いることができる。 As mentioned above, ergothioneine or its salts are known to exhibit various physiological activities and health functions, such as antioxidant effects, brain function improvement effects, anti-aging effects, eye disease improvement effects, whitening effects, It is known for its ultraviolet absorbing effect, melanin production suppressing effect, active oxygen species scavenging effect, elastase activity inhibiting effect, wrinkle formation suppressing effect, skin sagging suppressing effect, autophagy promoting effect, etc.
Therefore, the composition of the present invention can be used for antioxidant purposes, for improving brain function, for anti-aging, for eye diseases, for whitening, for absorbing ultraviolet rays, for suppressing melanin production, for eliminating reactive oxygen species, and for inhibiting elastase activity. It can be suitably used for suppressing wrinkle formation, suppressing skin sagging, promoting autophagy, etc.
コラーゲンについては、肌の保湿性、弾力性を向上するなどの美肌効果や、血液流動性を改善する効果など様々な健康機能を発揮することが知られている。本発明の組成物は重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを含有することから、コラーゲンにより発揮される上記の効果を得るために使用することもできる。
Collagen is known to exert various health functions such as beautifying the skin by improving skin moisture retention and elasticity, and improving blood fluidity. Since the composition of the present invention contains pig-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000, it can also be used to obtain the above-mentioned effects exerted by collagen.
本発明の組成物は、治療的用途（医療用途）又は非治療的用途（非医療用途）のいずれにも適用することができる。非治療的とは、医療行為、すなわち人間の手術、治療又は診断を含まない概念である。
The compositions of the invention can be applied for either therapeutic (medical) or non-therapeutic (non-medical) uses. Non-therapeutic is a concept that does not include medical procedures, ie, surgery, treatment, or diagnosis of humans.
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等に配合して使用される素材又は製剤等であってもよい。
The composition of the present invention can be in the form of a food or drink, a drug, a quasi-drug, a feed, or the like. The composition of the present invention may be a material or a preparation used by being mixed into foods and drinks, pharmaceuticals, quasi-drugs, feeds, and the like.
本発明の組成物は、経口用組成物であり、経口組成物として具体的には、飲食品、経口用の医薬品、医薬部外品、飼料等が挙げられ、好ましくは飲食品又は経口用の医薬品であり、より好ましくは飲食品である。
The composition of the present invention is an oral composition, and specific examples of the oral composition include food and drink products, oral pharmaceuticals, quasi-drugs, feeds, etc., and preferably food and drink products or oral compositions. It is a medicine, and more preferably a food or drink.
本発明の組成物は、本発明の効果を損なわない限り、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンに加えて、任意の添加剤、任意の成分を含有することができる。これらの添加剤及び成分は、組成物の形態等に応じて選択することができ、一般的に飲食品、医薬品、医薬部外品、飼料等の経口組成物に使用可能なものが使用できる。本発明の組成物を、飲食品、医薬品、医薬部外品、飼料等とする場合、その製造方法は特に限定されず、一般的な方法により製造することができる。一態様において、本発明の組成物は、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンからなるものであってもよい。
本発明の経口組成物の形態は特に限定されず、固体状（粉末状、顆粒状、タブレット状等）、液状、ペースト状等であってよい。 The composition of the present invention contains, in addition to ergothioneine or a salt thereof and porcine collagen having a weight average molecular weight of more than 1,000 and less than 10,000, any additives and ingredients, as long as the effects of the present invention are not impaired. can do. These additives and components can be selected depending on the form of the composition, etc., and those that can be generally used in oral compositions such as foods and drinks, pharmaceuticals, quasi-drugs, and feeds can be used. When the composition of the present invention is used as a food or drink, a drug, a quasi-drug, a feed, etc., the manufacturing method thereof is not particularly limited, and it can be manufactured by a general method. In one embodiment, the composition of the present invention may consist of ergothioneine or a salt thereof and a pig-derived collagen having a weight average molecular weight of greater than 1,000 and less than or equal to 10,000.
The form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
本発明の経口組成物の形態は特に限定されず、固体状（粉末状、顆粒状、タブレット状等）、液状、ペースト状等であってよい。 The composition of the present invention contains, in addition to ergothioneine or a salt thereof and porcine collagen having a weight average molecular weight of more than 1,000 and less than 10,000, any additives and ingredients, as long as the effects of the present invention are not impaired. can do. These additives and components can be selected depending on the form of the composition, etc., and those that can be generally used in oral compositions such as foods and drinks, pharmaceuticals, quasi-drugs, and feeds can be used. When the composition of the present invention is used as a food or drink, a drug, a quasi-drug, a feed, etc., the manufacturing method thereof is not particularly limited, and it can be manufactured by a general method. In one embodiment, the composition of the present invention may consist of ergothioneine or a salt thereof and a pig-derived collagen having a weight average molecular weight of greater than 1,000 and less than or equal to 10,000.
The form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
例えば本発明の組成物を飲食品とする場合、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンに、飲食品に使用可能な成分（例えば、食品素材、必要に応じて使用される食品添加物等）を配合して、種々の飲食品とすることができる。飲食品は特に限定されず、例えば、一般的な飲食品、健康食品、健康補助食品、健康飲料、機能性表示食品、特定保健用食品、病者用飲食品等が挙げられる。上記健康食品、健康補助食品、機能性表示食品、特定保健用食品等は、例えば、細粒剤、錠剤、顆粒剤、散剤、カプセル剤、チュアブル剤、ドライシロップ剤、シロップ剤、液剤、飲料、ドリンク剤、流動食等の各種製剤形態として使用することができる。
For example, when the composition of the present invention is used as a food or drink, ergothioneine or a salt thereof and porcine-derived collagen having a weight average molecular weight of more than 1,000 and less than 10,000 are combined with ingredients that can be used in foods and drinks (e.g., food materials, as necessary). Various food and drink products can be prepared by blending food additives (accordingly used food additives, etc.). Foods and drinks are not particularly limited, and include, for example, general foods and drinks, health foods, health supplements, health drinks, foods with functional claims, foods for specified health uses, foods and drinks for patients, and the like. The above health foods, health supplements, foods with functional claims, foods for specified health uses, etc. include fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used in various formulations such as tablets and liquid foods.
本発明の組成物を医薬品又は医薬部外品とする場合、例えば、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンに、薬理学的に許容される担体、必要に応じて添加される添加剤等を配合して、各種剤形の医薬品又は医薬部外品とすることができる。そのような担体、添加剤等は、医薬品又は医薬部外品に使用可能な、薬理学的に許容されるものであればよく、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、抗酸化剤、着色剤等の１又は２以上が挙げられる。医薬品又は医薬部外品の経口投与のための剤形としては、液剤、錠剤、散剤、細粒剤、顆粒剤、糖衣錠、カプセル剤、懸濁液、乳剤、チュアブル剤等が挙げられる。
When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, ergothioneine or a salt thereof and porcine collagen having a weight average molecular weight of more than 1,000 and less than 10,000 are combined with a pharmacologically acceptable carrier, as necessary. By blending additives and the like that are added according to the conditions, various dosage forms of pharmaceuticals or quasi-drugs can be made. Such carriers, additives, etc. may be pharmacologically acceptable ones that can be used in pharmaceuticals or quasi-drugs, such as excipients, binders, disintegrants, lubricants, One or more of antioxidants, colorants, etc. may be used. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables, and the like.
本発明の組成物を飼料とする場合には、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを飼料に配合すればよい。飼料には飼料添加剤も含まれる。飼料としては、例えば、牛、豚、鶏、羊、馬等に用いる家畜用飼料；ウサギ、ラット、マウス等に用いる小動物用飼料；犬、猫、小鳥等に用いるペットフードなどが挙げられる。
When the composition of the present invention is used as feed, ergothioneine or a salt thereof and collagen derived from pigs having a weight average molecular weight of more than 1,000 and less than 10,000 may be added to the feed. Feed also includes feed additives. Examples of the feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.
本発明の組成物を摂取させる又は投与する対象（投与対象ということもできる）は、特に限定されない。好ましくはヒト又は非ヒト哺乳動物であり、より好ましくはヒトである。
The subject to whom the composition of the present invention is ingested or administered (also referred to as the subject of administration) is not particularly limited. Preferably it is a human or non-human mammal, more preferably a human.
本発明は、以下の方法も包含する。
（Ａ）エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法であって、上記経口組成物に（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを配合する工程を含む、エルゴチオネイン又はその塩に由来する苦味を抑制する方法。 The present invention also includes the following method.
(A) A method for suppressing the bitter taste derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or a salt thereof, the oral composition comprising: A method for suppressing bitterness derived from ergothioneine or a salt thereof, the method comprising the step of blending collagen derived from ergothioneine or a salt thereof.
（Ａ）エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法であって、上記経口組成物に（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを配合する工程を含む、エルゴチオネイン又はその塩に由来する苦味を抑制する方法。 The present invention also includes the following method.
(A) A method for suppressing the bitter taste derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or a salt thereof, the oral composition comprising: A method for suppressing bitterness derived from ergothioneine or a salt thereof, the method comprising the step of blending collagen derived from ergothioneine or a salt thereof.
上記の方法により、エルゴチオネイン又はその塩に由来する苦味を効果的に抑制することが可能となる。
上記の方法において、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲン並びにそれらの好ましい態様は、上述した本発明の組成物と同じである。 The above method makes it possible to effectively suppress the bitter taste derived from ergothioneine or its salt.
In the above method, ergothioneine or a salt thereof, a pig-derived collagen having a weight average molecular weight of more than 1000 and less than 10000, and preferred embodiments thereof are the same as in the composition of the present invention described above.
上記の方法において、エルゴチオネイン又はその塩及び重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲン並びにそれらの好ましい態様は、上述した本発明の組成物と同じである。 The above method makes it possible to effectively suppress the bitter taste derived from ergothioneine or its salt.
In the above method, ergothioneine or a salt thereof, a pig-derived collagen having a weight average molecular weight of more than 1000 and less than 10000, and preferred embodiments thereof are the same as in the composition of the present invention described above.
上記の方法において、成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の配合比は特に制限されないが、好ましい範囲としては、本発明の組成物における、成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）の重量比と同じである。
中でも、経口組成物中の成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００となるように成分（Ｂ）を配合すると、成分（Ａ）に由来する苦味と成分（Ｂ）に由来する臭みのいずれも抑制することができ、好ましい。 In the above method, the blending ratio of component (B) to component (A) (in terms of ergothioneine) is not particularly limited, but the preferred range is the component (A) in the composition of the present invention (in terms of ergothioneine). It is the same as the weight ratio of (B).
Among these, when component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700, component ( Both the bitterness originating from A) and the odor originating from component (B) can be suppressed, which is preferable.
中でも、経口組成物中の成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００となるように成分（Ｂ）を配合すると、成分（Ａ）に由来する苦味と成分（Ｂ）に由来する臭みのいずれも抑制することができ、好ましい。 In the above method, the blending ratio of component (B) to component (A) (in terms of ergothioneine) is not particularly limited, but the preferred range is the component (A) in the composition of the present invention (in terms of ergothioneine). It is the same as the weight ratio of (B).
Among these, when component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700, component ( Both the bitterness originating from A) and the odor originating from component (B) can be suppressed, which is preferable.
上記の方法によって、エルゴチオネイン又はその塩に由来する苦味を抑制することができるが、他の苦味抑制方法と組み合わせてもよい。
他の苦味抑制方法としては例えば、苦味を有する成分に甘味剤又は矯味剤を添加して製剤化する方法、苦味を有する成分を糖衣で被覆して製剤化する方法、又はカプセルに封入して製剤化する方法等が挙げられる。 Although the above method can suppress the bitter taste derived from ergothioneine or its salt, it may be combined with other bitter taste suppression methods.
Other methods for suppressing bitterness include, for example, adding a sweetener or flavoring agent to a bitter component to formulate a formulation, coating the bitter component with sugar coating, or encapsulating it in a capsule. Examples include methods of converting
他の苦味抑制方法としては例えば、苦味を有する成分に甘味剤又は矯味剤を添加して製剤化する方法、苦味を有する成分を糖衣で被覆して製剤化する方法、又はカプセルに封入して製剤化する方法等が挙げられる。 Although the above method can suppress the bitter taste derived from ergothioneine or its salt, it may be combined with other bitter taste suppression methods.
Other methods for suppressing bitterness include, for example, adding a sweetener or flavoring agent to a bitter component to formulate a formulation, coating the bitter component with sugar coating, or encapsulating it in a capsule. Examples include methods of converting
本明細書において下限値と上限値によって表されている数値範囲、即ち「下限値～上限値」は、それら下限値及び上限値を含む。例えば、「１～２」により表される範囲は、１以上２以下を意味し、１及び２を含む。本明細書において、上限及び下限は、いずれの組み合わせによる範囲としてもよい。
In this specification, the numerical range expressed by a lower limit value and an upper limit value, ie, "lower limit value to upper limit value" includes the lower limit value and upper limit value. For example, the range represented by "1 to 2" means 1 or more and 2 or less, and includes 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.
以下、本発明を実施例に基づいてより具体的に説明する。尚、本発明はこれらの実施例に限定されるものではない。
Hereinafter, the present invention will be described in more detail based on Examples. Note that the present invention is not limited to these examples.
下記の評価試験で使用した材料は以下のとおりである。
（Ａ）エルゴチオネイン：Ｌ－エルゴチオネイン１００％含有原料
（Ｂ）コラーゲン：重量平均分子量が５０００の豚由来コラーゲン１００％含有原料 The materials used in the evaluation test below are as follows.
(A) Ergothioneine: Raw material containing 100% L-ergothioneine (B) Collagen: Raw material containing 100% pig-derived collagen with a weight average molecular weight of 5000
（Ａ）エルゴチオネイン：Ｌ－エルゴチオネイン１００％含有原料
（Ｂ）コラーゲン：重量平均分子量が５０００の豚由来コラーゲン１００％含有原料 The materials used in the evaluation test below are as follows.
(A) Ergothioneine: Raw material containing 100% L-ergothioneine (B) Collagen: Raw material containing 100% pig-derived collagen with a weight average molecular weight of 5000
コラーゲンの重量平均分子量は、中国国家標準規格（ＧＢ規格）ＧＢ／Ｔ ２２７２９－２００８ フィッシュオリゴペプチドパウダーに関する相対分子質量測定法にて測定した。ただし、Ｍ，４５１及びＭ，１８９の試薬については、それぞれグリシン－グリシン－チロシン－アルギニン（Ｍ，４５１）、グリシン－グリシン－グリシン（Ｍ，１８９）を用いた。
The weight average molecular weight of collagen was measured using the Chinese National Standard (GB Standard) GB/T 22729-2008 relative molecular mass measurement method for fish oligopeptide powder. However, for the reagents M,451 and M,189, glycine-glycine-tyrosine-arginine (M,451) and glycine-glycine-glycine (M,189) were used, respectively.
＜実施例１：エルゴチオネイン及びコラーゲンを含む経口組成物についての香味評価試験＞
エルゴチオネイン及びコラーゲンを含む経口組成物を調製し、官能評価に熟練したパネラー３名が官能評価を行った。
表１に示す量の上記（Ａ）及び（Ｂ）を混合して、試料１～６の組成物（エルゴチオネイン及びコラーゲンを含有する経口組成物）を調製した。各組成物中の（Ａ）エルゴチオネインに対する（Ｂ）コラーゲンの重量比（（Ｂ）／（Ａ））を表１に示す。
各パネラーが、調製した経口組成物の全量（例えば、試料１ではエルゴチオネイン１０ｍｇ及びコラーゲン１０ｍｇの合計２０ｍｇ）を直接舌の上にのせて、エルゴチオネイン由来の苦味の強度及びコラーゲン由来の臭みの強度を以下の基準に従って評価した。 <Example 1: Flavor evaluation test for oral composition containing ergothioneine and collagen>
An oral composition containing ergothioneine and collagen was prepared, and three panelists skilled in sensory evaluation performed sensory evaluation.
Compositions of Samples 1 to 6 (oral compositions containing ergothioneine and collagen) were prepared by mixing the amounts of (A) and (B) shown in Table 1. Table 1 shows the weight ratio of (B) collagen to (A) ergothioneine ((B)/(A)) in each composition.
Each panelist placed the entire amount of the prepared oral composition (for example, in sample 1, 10 mg of ergothioneine and 10 mg of collagen, a total of 20 mg) on their tongue, and evaluated the intensity of the bitter taste derived from ergothioneine and the intensity of the odor derived from collagen as follows. It was evaluated according to the criteria of
エルゴチオネイン及びコラーゲンを含む経口組成物を調製し、官能評価に熟練したパネラー３名が官能評価を行った。
表１に示す量の上記（Ａ）及び（Ｂ）を混合して、試料１～６の組成物（エルゴチオネイン及びコラーゲンを含有する経口組成物）を調製した。各組成物中の（Ａ）エルゴチオネインに対する（Ｂ）コラーゲンの重量比（（Ｂ）／（Ａ））を表１に示す。
各パネラーが、調製した経口組成物の全量（例えば、試料１ではエルゴチオネイン１０ｍｇ及びコラーゲン１０ｍｇの合計２０ｍｇ）を直接舌の上にのせて、エルゴチオネイン由来の苦味の強度及びコラーゲン由来の臭みの強度を以下の基準に従って評価した。 <Example 1: Flavor evaluation test for oral composition containing ergothioneine and collagen>
An oral composition containing ergothioneine and collagen was prepared, and three panelists skilled in sensory evaluation performed sensory evaluation.
Compositions of Samples 1 to 6 (oral compositions containing ergothioneine and collagen) were prepared by mixing the amounts of (A) and (B) shown in Table 1. Table 1 shows the weight ratio of (B) collagen to (A) ergothioneine ((B)/(A)) in each composition.
Each panelist placed the entire amount of the prepared oral composition (for example, in sample 1, 10 mg of ergothioneine and 10 mg of collagen, a total of 20 mg) on their tongue, and evaluated the intensity of the bitter taste derived from ergothioneine and the intensity of the odor derived from collagen as follows. It was evaluated according to the criteria of
（エルゴチオネイン由来の苦味の評価基準）
下記の基準で１～５点（５段階）で評価した。基準点として、原料（Ａ）（１０ｍｇ）を舌の上にのせた場合に感じられたエルゴチオネイン由来の苦味の強度を５点とした（コントロール１）。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
５点：エルゴチオネイン由来の苦味を強く感じる
４点：エルゴチオネイン由来の苦味を感じる
３点：エルゴチオネイン由来の苦味を少し感じる
２点：エルゴチオネイン由来の苦味をあまり感じない
１点：エルゴチオネイン由来の苦味を感じない (Evaluation criteria for bitterness derived from ergothioneine)
Evaluation was made on a scale of 1 to 5 (5 levels) based on the following criteria. As a reference point, the intensity of the bitter taste derived from ergothioneine felt when raw material (A) (10 mg) was placed on the tongue was given a score of 5 (Control 1).
The evaluations of the three panelists were totaled, and the average value (score) is shown in Table 1.
5 points: I strongly feel the bitterness from ergothioneine 4 points: I feel the bitterness from ergothioneine 3 points: I feel a little bitterness from ergothioneine 2 points: I don't really feel the bitterness from ergothioneine 1 point: I don't feel the bitterness from ergothioneine
下記の基準で１～５点（５段階）で評価した。基準点として、原料（Ａ）（１０ｍｇ）を舌の上にのせた場合に感じられたエルゴチオネイン由来の苦味の強度を５点とした（コントロール１）。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
５点：エルゴチオネイン由来の苦味を強く感じる
４点：エルゴチオネイン由来の苦味を感じる
３点：エルゴチオネイン由来の苦味を少し感じる
２点：エルゴチオネイン由来の苦味をあまり感じない
１点：エルゴチオネイン由来の苦味を感じない (Evaluation criteria for bitterness derived from ergothioneine)
Evaluation was made on a scale of 1 to 5 (5 levels) based on the following criteria. As a reference point, the intensity of the bitter taste derived from ergothioneine felt when raw material (A) (10 mg) was placed on the tongue was given a score of 5 (Control 1).
The evaluations of the three panelists were totaled, and the average value (score) is shown in Table 1.
5 points: I strongly feel the bitterness from ergothioneine 4 points: I feel the bitterness from ergothioneine 3 points: I feel a little bitterness from ergothioneine 2 points: I don't really feel the bitterness from ergothioneine 1 point: I don't feel the bitterness from ergothioneine
（コラーゲン由来の臭みの評価基準）
下記の基準で１～５点（５段階）で評価した。基準点として、原料（Ｂ）（１０ｍｇ）を舌の上にのせた場合に感じられたコラーゲン由来の苦味の強度を５点とした（コントロール２）。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
５点：コラーゲン由来の臭みを強く感じる
４点：コラーゲン由来の臭みを感じる
３点：コラーゲン由来の臭みを少し感じる
２点：コラーゲン由来の臭みをあまり感じない
１点：コラーゲン由来の臭みを感じない (Evaluation criteria for collagen-derived odor)
Evaluation was made on a scale of 1 to 5 (5 levels) based on the following criteria. As a reference point, the intensity of the collagen-derived bitterness felt when raw material (B) (10 mg) was placed on the tongue was given a score of 5 (Control 2).
The evaluations of the three panelists were totaled, and the average value (score) is shown in Table 1.
5 points: I feel a strong odor derived from collagen 4 points: I feel an odor derived from collagen 3 points: I feel a slight odor derived from collagen 2 points: I do not really feel an odor derived from collagen 1 point: I do not feel an odor derived from collagen
下記の基準で１～５点（５段階）で評価した。基準点として、原料（Ｂ）（１０ｍｇ）を舌の上にのせた場合に感じられたコラーゲン由来の苦味の強度を５点とした（コントロール２）。
３名のパネラーの評価を集計し、平均値（点）を表１に示す。
５点：コラーゲン由来の臭みを強く感じる
４点：コラーゲン由来の臭みを感じる
３点：コラーゲン由来の臭みを少し感じる
２点：コラーゲン由来の臭みをあまり感じない
１点：コラーゲン由来の臭みを感じない (Evaluation criteria for collagen-derived odor)
Evaluation was made on a scale of 1 to 5 (5 levels) based on the following criteria. As a reference point, the intensity of the collagen-derived bitterness felt when raw material (B) (10 mg) was placed on the tongue was given a score of 5 (Control 2).
The evaluations of the three panelists were totaled, and the average value (score) is shown in Table 1.
5 points: I feel a strong odor derived from collagen 4 points: I feel an odor derived from collagen 3 points: I feel a slight odor derived from collagen 2 points: I do not really feel an odor derived from collagen 1 point: I do not feel an odor derived from collagen
＜結果＞
エルゴチオネインとコラーゲンとを組み合わせることにより、エルゴチオネイン由来の苦味が抑制されることを確認した。
コラーゲンについても、コラーゲンのみでは臭みが強く摂取しにくいが、適量のエルゴチオネインと組み合わせることにより、臭みの程度が緩和されることを確認した。
<Results>
It was confirmed that the bitter taste derived from ergothioneine was suppressed by combining ergothioneine and collagen.
Collagen alone has a strong odor and is difficult to ingest, but it was confirmed that the odor can be alleviated by combining it with an appropriate amount of ergothioneine.
エルゴチオネインとコラーゲンとを組み合わせることにより、エルゴチオネイン由来の苦味が抑制されることを確認した。
コラーゲンについても、コラーゲンのみでは臭みが強く摂取しにくいが、適量のエルゴチオネインと組み合わせることにより、臭みの程度が緩和されることを確認した。
<Results>
It was confirmed that the bitter taste derived from ergothioneine was suppressed by combining ergothioneine and collagen.
Collagen alone has a strong odor and is difficult to ingest, but it was confirmed that the odor can be alleviated by combining it with an appropriate amount of ergothioneine.
Claims (5)
- 下記の成分（Ａ）及び（Ｂ）：
（Ａ）エルゴチオネイン又はその塩、及び、
（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲン、
を含有する経口組成物。 Ingredients (A) and (B) below:
(A) ergothioneine or a salt thereof, and
(B) Pig-derived collagen having a weight average molecular weight of more than 1000 and less than 10000;
An oral composition containing. - 成分（Ａ）（エルゴチオネイン換算）に対する、成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００である、請求項１に記載の経口組成物。 The oral composition according to claim 1, wherein the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) is 5 to 700.
- 飲食品である、請求項１又は２に記載の経口組成物。 The oral composition according to claim 1 or 2, which is a food or drink.
- （Ａ）エルゴチオネイン又はその塩を含有する経口組成物におけるエルゴチオネイン又はその塩に由来する苦味を抑制する方法であって、
前記経口組成物に（Ｂ）重量平均分子量が１０００より大きく１００００以下であるブタ由来のコラーゲンを配合する工程を含む、エルゴチオネイン又はその塩に由来する苦味を抑制する方法。 (A) A method for suppressing bitterness derived from ergothioneine or a salt thereof in an oral composition containing ergothioneine or a salt thereof, comprising:
A method for suppressing bitterness derived from ergothioneine or a salt thereof, comprising the step of blending (B) porcine-derived collagen having a weight average molecular weight of more than 1,000 and 10,000 or less into the oral composition. - 経口組成物中の成分（Ａ）（エルゴチオネイン換算）に対する成分（Ｂ）の重量比（（Ｂ）／（Ａ））が５～７００となるように成分（Ｂ）を配合する、請求項４に記載の方法。 Claim 4, wherein component (B) is blended so that the weight ratio ((B)/(A)) of component (B) to component (A) (in terms of ergothioneine) in the oral composition is 5 to 700. Method described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022123869 | 2022-08-03 | ||
| JP2022-123869 | 2022-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024029392A1 true WO2024029392A1 (en) | 2024-02-08 |
Family
ID=89848953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/027091 WO2024029392A1 (en) | 2022-08-03 | 2023-07-25 | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW202415371A (en) |
| WO (1) | WO2024029392A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103976228A (en) * | 2014-04-15 | 2014-08-13 | 柳培健 | Pork trotter beautifying porridge and preparation method thereof |
| JP2015042151A (en) * | 2013-08-26 | 2015-03-05 | 理研ビタミン株式会社 | Mushroom extract processed product and method for producing the same |
| CN110432492A (en) * | 2019-08-26 | 2019-11-12 | 江南大学 | A kind of hypoglycemic nano-clathrate and preparation method thereof |
| US20190373914A1 (en) * | 2018-06-11 | 2019-12-12 | Board Of Trustees Of Michigan State University | Foodstuff Having Increased Protein Content |
| CN112106985A (en) * | 2020-08-03 | 2020-12-22 | 李想 | Protein molecular peptide formula for regulating blood sugar |
| CN112913996A (en) * | 2021-03-18 | 2021-06-08 | 乐山绿水青山科技有限公司 | Rosa roxburghii Tratt liquid for improving sleep quality and preparation method thereof |
| KR20230008571A (en) * | 2021-07-07 | 2023-01-16 | (주)조은음식드림 | Oriental pork with improved meat quality through ripening liquid and oriental broth. |
-
2023
- 2023-07-25 WO PCT/JP2023/027091 patent/WO2024029392A1/en unknown
- 2023-08-02 TW TW112129039A patent/TW202415371A/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015042151A (en) * | 2013-08-26 | 2015-03-05 | 理研ビタミン株式会社 | Mushroom extract processed product and method for producing the same |
| CN103976228A (en) * | 2014-04-15 | 2014-08-13 | 柳培健 | Pork trotter beautifying porridge and preparation method thereof |
| US20190373914A1 (en) * | 2018-06-11 | 2019-12-12 | Board Of Trustees Of Michigan State University | Foodstuff Having Increased Protein Content |
| CN110432492A (en) * | 2019-08-26 | 2019-11-12 | 江南大学 | A kind of hypoglycemic nano-clathrate and preparation method thereof |
| CN112106985A (en) * | 2020-08-03 | 2020-12-22 | 李想 | Protein molecular peptide formula for regulating blood sugar |
| CN112913996A (en) * | 2021-03-18 | 2021-06-08 | 乐山绿水青山科技有限公司 | Rosa roxburghii Tratt liquid for improving sleep quality and preparation method thereof |
| KR20230008571A (en) * | 2021-07-07 | 2023-01-16 | (주)조은음식드림 | Oriental pork with improved meat quality through ripening liquid and oriental broth. |
Non-Patent Citations (2)
| Title |
|---|
| "Comparative quantitative analysis of ergothioneine in mushrooms", 7 February 2018 (2018-02-07), Retrieved from the Internet <URL:https://www.mst.or.jpPortals0casepdfc0345.pdf c0345> [retrieved on 20230926] * |
| "Fungi life with Ergothioneine", 23 September 2020 (2020-09-23), Retrieved from the Internet <URL:https://web.archive.org/web/20200923144404/https://www.hokto-kinoko.co.jp/kinokolabo/jiten/jiten12/> * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202415371A (en) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3040992B2 (en) | Food composition | |
| US20040029955A1 (en) | Composition for use in prevention or treatment of vascular-related diseases | |
| KR20190086421A (en) | Companion animal nutrient containing collagen extract and method for producing the same | |
| WO2024029392A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof | |
| WO2022230491A1 (en) | Composition for ameliorating or suppressing decline of kidney functions | |
| WO2022230493A1 (en) | Composition for increasing leukocytes and/or basophils | |
| JP4707401B2 (en) | Antioxidant peptides from royal jelly | |
| JP2011116761A (en) | Antioxidative peptide derived from royal jelly | |
| WO2024029393A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material | |
| WO2024018956A1 (en) | Oral composition, and method for suppressing bitterness originating from ergothioneine or salt thereof and odor originating from chondroitin sulfate or salt thereof | |
| WO2024018955A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine and off-flavor derived from glucosamine compound | |
| WO2023120367A1 (en) | Oral composition and method for suppressing bitterness derived from ergothioneine | |
| WO2023120376A1 (en) | ORAL COMPOSITION, AND METHOD FOR SUPPRESSING BITTERNESS DERIVED FROM ERGOTHIONEINE AND ODOR DERIVED FROM CEREAL OIL OR γ-ORYZANOL | |
| WO2024172002A1 (en) | Vasodilation composition containing ergothioneine | |
| WO2023120368A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid | |
| WO2023120370A1 (en) | Oral composition and method for minimizing bitter taste resulting from ergothioneine or salt thereof and odor resulting from vitamin e | |
| WO2023120378A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and smell derived from arachidonic acids | |
| TW202342004A (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid | |
| WO2023090260A1 (en) | Composition for inhibiting histamine-n-methyltransferase | |
| CN111700920A (en) | Physiological function active agent and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23849947 Country of ref document: EP Kind code of ref document: A1 |